Which medication is administered to manage the adverse effects of topotecan in ovarian cancer patients?

Granisetron is often utilized to manage the nausea and vomiting that can be a significant adverse effect of chemotherapy agents such as topotecan, especially in patients with ovarian cancer. This medication works as a selective serotonin 5-HT3 receptor antagonist, effectively preventing nausea and vomiting associated with cancer treatment.

The transdermal patch form of granisetron is particularly convenient for patients, allowing for continuous medication release and minimizing the need for frequent dosing, thus improving adherence and comfort during treatment. The timing and administration method help address chemotherapy-induced nausea proactively.

While other options provide antiemetic effects, granisetron's specific efficacy as a 5-HT3 receptor antagonist, along with the benefits of transdermal delivery, positions it as the preferred choice for managing chemotherapy-related nausea in this context.